All In Biotech

NDA 021687 · Organon

Vytorin

Ezetimibe, Simvastatin · Oral · Dietary Cholesterol Absorption Inhibitor; HMG-CoA Reductase Inhibitor

Last checked: Nov 20, 2026Latest source record: Mar 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Jul 23, 2004

Approved uses

5

Original approval plus efficacy supplements

Registered trials

422

153 Phase 3, 37 recruiting

FAERS reports

15,138

9,500 serious, 857 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 21, 2026.

VYTORIN VYTORIN ® is a combination of simvastatin and ezetimibe indicated: As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): In adults with primary hyperlipidemia. In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of VYTORIN, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. VYTORIN is a combination of ezetimibe, a dietary cholesterol absorption inhibitor, and simvastatin, an HMG-CoA reductase inhibitor (statin) indicated: ( 1 ) As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): In adults with primary hyperlipidemia. In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C lowering therapies to reduce LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of VYTORIN, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral...

Mechanism: VYTORIN Plasma cholesterol is derived from intestinal absorption and endogenous synthesis. VYTORIN contains ezetimibe and simvastatin, two lipid-lowering compounds with complementary mechanisms of action. Ezetimibe Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols. Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • VYTORIN · EZETIMIBE 10MG; SIMVASTATIN 80MG · TABLET, ORAL · Prescription · TE AB
  • VYTORIN · EZETIMIBE 10MG; SIMVASTATIN 20MG · TABLET, ORAL · Prescription · TE AB
  • VYTORIN · EZETIMIBE 10MG; SIMVASTATIN 40MG · TABLET, ORAL · Prescription · TE AB
  • VYTORIN · EZETIMIBE 10MG; SIMVASTATIN 10MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ezetimibe" as an intervention, any sponsor and status, largest first.

All 422 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea1,013
  • drug ineffective821
  • fatigue777
  • dizziness734
  • pain708
  • myalgia675
  • dyspnoea647
  • diarrhoea605
  • asthenia604
  • headache566
  • pain in extremity550
  • arthralgia533

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200440
2005627
2006949
20071,301
20081,554
20091,189
20101,679
20111,130
2012987
2013801
2014830
2015912
2016751
2017563
2018447
2019407
2020250
2021197
2022132
202397
202498
2025110
202687

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vytorin (Ezetimibe/Simvastatin)

2024 spending

$4.3M

Beneficiaries

1,203

5,246 claims

Per beneficiary

$3,572

$12.40 per unit

View as table
YearSpending
2020$0
2021$1,767,362
2022$5,606,613
2023$5,039,586
2024$4,297,632

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 976 on PubMed

Sponsor: Organon

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.